Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | TYMP | P19971 | 11/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22783664 | 0.77 | JAK2 (0.61) | JAK2THRBDHODHLMNAALDH1A1 | |
| SCHEMBL24761226 | 0.75 | CYP1A2 (0.42) | JAK2THRBTYMPPNPDHODH | |
| SCHEMBL10962665 | 0.74 | JAK2 (0.59) | JAK2THRBTYMPDHODHLMNA | |
| SCHEMBL25391975 | 0.74 | JAK2 (0.59) | JAK2THRBDHODHLMNAALDH1A1 | |
| SCHEMBL11130450 | 0.73 | JAK2 (0.57) | JAK2THRBTYMPDHODHLMNA | |
| SCHEMBL122310 | 0.73 | JAK2 (0.57) | JAK2THRBTYMPDHODH | |
| SCHEMBL9715507 | 0.73 | JAK2 (1.00) | JAK2THRBTYMPDHODHLMNA | |
| SCHEMBL44527 | 0.73 | JAK2 (1.00) | JAK2THRBTYMPDHODHLMNA | |
| SCHEMBL2894307 | 0.73 | JAK2 (0.57) | JAK2THRBTYMPGPR35DHODH | |
| SCHEMBL190140 | 0.73 | JAK2 (0.57) | JAK2THRBTYMPPNPDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0445239-A4 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | — | 1992-03-25 | — | — | EP | claimed |
| EP-0445239-A1 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-09-11 | — | — | EP | claimed |
| WO-1991000081-A2 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-01-10 | — | — | WO | claimed |
| WO-2022194191-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12D | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-09-22 | — | — | WO | disclosed |
| CN-114470108-A | Compound isatis root buccal tablet and processing method thereof | 徐昊 | 2022-05-13 | — | — | CN | disclosed |
| US-8334292-B1 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110150961-A1 | ANTI-INFECTIVE CATHETERS | ANGIOTECH INTERNATIONAL AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2254640-A2 | ANTI-INFECTIVE CATHETERS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009105484-A2 | ANTI-INFECTIVE CATHETERS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2009-08-27 | — | — | WO | disclosed |
| US-20050153357-A1 | Bioactive sensors | EICHLER JUTTA (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6159953-A | Anti-malarial composition and method of use | CATHOLIC UNIVERSITY OF AMERICA (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0445239-A4 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | — | 1992-03-25 | — | — | EP | disclosed |
| EP-0445239-A1 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991000081-A2 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-01-10 | — | — | WO | disclosed |
| US-4045556-A | ANTIDEPRESSANTS, PYSCHOSTIMULANTS; SILYLATION | SCHWERTNER EBERHARD | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150961-A1 | ANTI-INFECTIVE CATHETERS | NACA, PUF60, POLR1C | JAK2 2147/4885THRB 4075/4885TYMP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.